
InVivo Therapeutics to sell stake in company; shares drop
pharmafile | March 15, 2016 | News story | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing |Â Â InVivo Therapeutics, Stake sale, stocksÂ
InVivo Therapeutics (Nasdaq: NVIV) said it plans to sell an additional stake in the company to raise funds for its ongoing clinical trials.
The clinical-stage biotechnology company said it plans to float a public offering of stock and warrants, packaged as units. No details about the pricing, volumes and terms were disclosed.
The company said the proceeds will also be used for general corporate purposes.
Shares in the company closed down $0.43 to $8.65 on the Nasdaq.
Anjali Shukla
Related Content

Profits over patients: US pharma spending billions on investor payouts
In 2017 Donald Trump signed the Tax Cuts and Jobs Act (TCJA), creating billions of …

ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had …

Shares in Mirati plummet after disappointing Phase II trial
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing …






